Format

Send to

Choose Destination
Z Rheumatol. 2016 Sep;75(7):681-6. doi: 10.1007/s00393-016-0142-y.

Treatment of IgG4-related disease : Current and future approaches.

Author information

1
Division of Rheumatology, Allergy, & Immunology, Massachusetts General Hospital, Boston, MA, USA.
2
Harvard Medical School; The Edward Fox Chair in Medicine, Massachusetts General Hospital, Boston, MA, USA. jhstone@mgh.harvard.edu.
3
Rheumatology Clinic/Yawkey 2, Massachusetts General Hospital, 55 Fruit Street, 02114, Boston, MA, USA. jhstone@mgh.harvard.edu.

Abstract

IgG4-related disease (IgG4-RD) is capable of causing great morbidity and even mortality if the condition remains undiagnosed or poorly treated, yet is typically a treatment-responsive disorder. Glucocorticoids have not been studied rigorously and practices with regard to dosing and duration of treatment remain largely empiric. In addition, IgG4-RD patients are often particularly susceptible to and intolerant of the deleterious effects of glucocorticoid therapy. B cell depletion with anti-CD20 monoclonal antibodies appears to be a rapid, effective means of obtaining disease control and limiting patients' glucocorticoid exposure, but this option is frequently not available. Other therapies targeting the B cell lineage may also be efficacious, and one is under study. The means by which depletion or inhibition of B cells and their progeny ameliorate IgG4-RD is coming into focus now through careful mechanistic studies of samples from treated patients. The mechanistic understanding of IgG4-RD will bring an array of specific targets for therapeutic intervention. Plasmablast-directed therapy with a CD19 monoclonal antibody is currently in clinical trials. CD4 + cytotoxic T lymphocytes and fibrosis, both observed nearly universally in the tissue of IgG4-RD patients, present two unexploited vulnerabilities in controlling and even reversing the effects of the disease. Further development of such therapies is a major goal of the next few years.

KEYWORDS:

Adverse effects; Antirheumatic agents; B-cells; Glucocorticoids; Monoclonal antibodies

PMID:
27431746
PMCID:
PMC5953192
DOI:
10.1007/s00393-016-0142-y
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Springer Icon for PubMed Central
Loading ...
Support Center